BCOP EXAM QUESTIONS LATEST
AND ANSWERS 2026 -
2027
melanoma - Stage I or II - ANSWERS-surgery
melanoma - Stage III - ANSWERS-nivolumab, ipilumumab
melanoma - BRAF positive Stage III - ANSWERS-dabrafenib +
trametinib
melanoma - BRAF positive Stage IV, aggressive, bulky, symptomatic -
ANSWERS-dabrafenib + trametinib, vemurafenib + cobimetinib
melanoma - Unresectable stage III with in-transit lesions - ANSWERS-
Talimogene Laherparepvec (T-VEC)
melanoma - Stage IV - ANSWERS-nivolumab, pembrolizumab
melanoma - BRAF positive Stage IV minimally symptomatic -
ANSWERS-nivolumab, pembrolizumab, nivolumab + ipilimumab
(Stage IV immunotherapy)
END OF
PAGE
1
,BCOP EXAM QUESTIONS LATEST
AND ANSWERS 2026 -
2027
metastatic basal cell carcinoma - ANSWERS-vismodegib, sonidegib
CLL - Age < 65 without significant comorbidies without del 17p/TP53 -
ANSWERS-FCR, ibrutinib, bendamustine with or without cd20 MoAb
CLL - Age < 65 without significant comorbidities without del 17p/TP53
relapse/refractory - ANSWERS-ibrutinib, idelalisib + R, venetoclax with
or without R
CLL - Age < 65 without significant comorbidies without del 17p/TP53
maintenance - ANSWERS-consider lenalidomide for high risk
CLL - Age > 65 or younger patients with significant comorbidities
without del 17p/TP53 - ANSWERS-Obinutuzumab + chlorambucil,
ibrutinib, ofatumumab + chlorambucil, rituxan + chlorambucil,
bendamustine with or without R
CLL - Age > 65 or younger patients with significant comorbidities
without del 17p/TP53 maintenance - ANSWERS-consider lenalidomide
for high risk
END OF
PAGE
2
,BCOP EXAM QUESTIONS LATEST
AND ANSWERS 2026 -
2027
CLL - Age > 65 or younger patients with significant comorbidities
without del 17p/TP53 relapse/refractory - ANSWERS-ibrutinib,
idelalisib + R, venetoclax with or without R
CLL - Frail patients with significant comorbidities without del 17p/TP53
- ANSWERS-Obinutuzumab + chlorambucil, ibrutinib, ofatumumab +
chlorambucil, rituxan + chlorambucil
CLL - Frail patients with significant comorbidities without del 17p/TP53
maintenance - ANSWERS-consider lenalidomide for high risk
Frail patients with significant comorbidities without del 17p/TP53
relapsed/refractory - ANSWERS-ibrutinib, idelalisib + R, venetoclax
with or without R
CLL - With del 17p/TP53 - ANSWERS-ibrutinib**, HDMP + rituxan,
obinutuzumab, alemtuzumab with or without rituxan
END OF
PAGE
3
, BCOP EXAM QUESTIONS LATEST
AND ANSWERS 2026 -
2027
CLL - With del 17p/TP53 relapsed/refractory - ANSWERS-ibrutinib,
idelalisib + R, venetoclax with or without R
CLL - With del 17p/TP53 maintenance - ANSWERS-consider
lenalidomide for high risk
NSCLC stage IA - ANSWERS-surgery
NSCLC stage IB - ANSWERS-surgery
NSCLC stage IIA - ANSWERS-surgery followed by cisplatin doublet
NSCLC stage IIB - ANSWERS-surgery followed by cisplatin doublet
NSCLC stage IIIA - ANSWERS-surgery followed by cisplatin doublet
NSCLC stage IIIB - ANSWERS-surgery followed by cisplatin doublet +
XRT
END OF
PAGE
4
AND ANSWERS 2026 -
2027
melanoma - Stage I or II - ANSWERS-surgery
melanoma - Stage III - ANSWERS-nivolumab, ipilumumab
melanoma - BRAF positive Stage III - ANSWERS-dabrafenib +
trametinib
melanoma - BRAF positive Stage IV, aggressive, bulky, symptomatic -
ANSWERS-dabrafenib + trametinib, vemurafenib + cobimetinib
melanoma - Unresectable stage III with in-transit lesions - ANSWERS-
Talimogene Laherparepvec (T-VEC)
melanoma - Stage IV - ANSWERS-nivolumab, pembrolizumab
melanoma - BRAF positive Stage IV minimally symptomatic -
ANSWERS-nivolumab, pembrolizumab, nivolumab + ipilimumab
(Stage IV immunotherapy)
END OF
PAGE
1
,BCOP EXAM QUESTIONS LATEST
AND ANSWERS 2026 -
2027
metastatic basal cell carcinoma - ANSWERS-vismodegib, sonidegib
CLL - Age < 65 without significant comorbidies without del 17p/TP53 -
ANSWERS-FCR, ibrutinib, bendamustine with or without cd20 MoAb
CLL - Age < 65 without significant comorbidities without del 17p/TP53
relapse/refractory - ANSWERS-ibrutinib, idelalisib + R, venetoclax with
or without R
CLL - Age < 65 without significant comorbidies without del 17p/TP53
maintenance - ANSWERS-consider lenalidomide for high risk
CLL - Age > 65 or younger patients with significant comorbidities
without del 17p/TP53 - ANSWERS-Obinutuzumab + chlorambucil,
ibrutinib, ofatumumab + chlorambucil, rituxan + chlorambucil,
bendamustine with or without R
CLL - Age > 65 or younger patients with significant comorbidities
without del 17p/TP53 maintenance - ANSWERS-consider lenalidomide
for high risk
END OF
PAGE
2
,BCOP EXAM QUESTIONS LATEST
AND ANSWERS 2026 -
2027
CLL - Age > 65 or younger patients with significant comorbidities
without del 17p/TP53 relapse/refractory - ANSWERS-ibrutinib,
idelalisib + R, venetoclax with or without R
CLL - Frail patients with significant comorbidities without del 17p/TP53
- ANSWERS-Obinutuzumab + chlorambucil, ibrutinib, ofatumumab +
chlorambucil, rituxan + chlorambucil
CLL - Frail patients with significant comorbidities without del 17p/TP53
maintenance - ANSWERS-consider lenalidomide for high risk
Frail patients with significant comorbidities without del 17p/TP53
relapsed/refractory - ANSWERS-ibrutinib, idelalisib + R, venetoclax
with or without R
CLL - With del 17p/TP53 - ANSWERS-ibrutinib**, HDMP + rituxan,
obinutuzumab, alemtuzumab with or without rituxan
END OF
PAGE
3
, BCOP EXAM QUESTIONS LATEST
AND ANSWERS 2026 -
2027
CLL - With del 17p/TP53 relapsed/refractory - ANSWERS-ibrutinib,
idelalisib + R, venetoclax with or without R
CLL - With del 17p/TP53 maintenance - ANSWERS-consider
lenalidomide for high risk
NSCLC stage IA - ANSWERS-surgery
NSCLC stage IB - ANSWERS-surgery
NSCLC stage IIA - ANSWERS-surgery followed by cisplatin doublet
NSCLC stage IIB - ANSWERS-surgery followed by cisplatin doublet
NSCLC stage IIIA - ANSWERS-surgery followed by cisplatin doublet
NSCLC stage IIIB - ANSWERS-surgery followed by cisplatin doublet +
XRT
END OF
PAGE
4
